

GENETICS AND GENOMICS DIAGNOSTIC LABORATORY

 $For local courier service and/or inquiries, please contact 513-636-4474 \bullet Fax: 513-636-4373 \\ www.cincinnatichildrens.org/diagnosticlabs \bullet Email: LabGeneticCounselors@cchmc.org$

Mailing Address:

3333 Burnet Avenue, Room R1042 Cincinnati, OH 45229

ONCOLOGY GENETIC TESTING REQUISITION

All Information Must Be Completed Before Sample Can Be Processed

PATIENT INFORMATION					
Patient Name:	Last	First	,		
Address:					
		MR#:			
Date of Birth:/ _		_ Gender: □ Male □ Female			
INDICATIONS/DIAGNOSIS/ICD-9 CODE					
□ Acute Myelogenous Leukemia □ Acute Promyelocytic Leukemia □ Adenopathy □ Anemia □ Burkitt Lymphoma □ Chronic Lymphocytic Leukemia □ Chronic Myelogenous Leukemia □ Colorectal cancer □ Ewing sarcoma	□ Glioma □ Hodgkin lymphoma □ Langerhans cell histiocytosis (LCH) □ Leukemia □ Leukocytosis □ Leukopenia □ Lung cancer □ Lymphocytosis □ Lymphoma	□ Lymphoproliferative disorder □ Malignant melanoma □ Medulloblastoma □ Monoclonal gammopathy □ Multiple Myeloma □ Myelodysplastic syndrome or disease (MDS) □ Myeloproliferative disease (MPS or MPD) □ Neutropenia □ Non-Hodgkin Lymphoma (NHL)	□ Pancytopenia □ Polycythemia Vera (PV) □ Sarcoma □ Thrombocytopenia □ Thrombocytosis □ Wilms tumor □ Other		
ETHNIC/RACIAL BACKGROUND (Choose All) BILLING INFORMATION (Choose ONE method of payment):					
□ European American (White) □ Native American or Alaskan □ Pacific Islander □ Latinx-Hispanic	☐ African-American (Black) ☐ Asian-American ☐ Ashkenazi Jewish ancestry	Accounts Payable Contact Name: Phone:			
REFERRII	NG PHYSICIAN	Email:			
Email: Genetic Counselor/Lab Contact Na Phone: ()	me: Fax: ()	Gender: Date of	Ested at the time of service. Figure Birth		
	estions (<i>if different than ordering provide</i>				



☐ Pilocytic Astrocytoma FISH Panel

Patient Name:	Date of Birth:
i diletti Natile.	Date of Birtii

SAMPLE/SPECIMEN INFORMATION

		DISEASE STATUS:	
Has natient received a hone m	arrow transplant?	☐ New diagnosis ☐ Remission ☐ Relapse ☐ E(COG) study ☐ COG patient	
If yes, date of bone marrow transplant		SPECIMEN TYPE — SEE PAGE 3 FOR SPECIMEN REQUIREMENTS	
Percent engraftment		☐ Bone marrow ☐ Oncology blood ☐ Lymph node	
		\square Formalin fixed paraffin embedded tissue \square Touch prep \square Smear	
		Estimated percent of tumor in sample:	
Specimen Date:	Time:	☐ Solid tumor (specify): ☐ If in media, type:	
DRAWN BY:		Estimated percent of tumor in sample:	
*Phlebotomist must initial tube of specimen to confirm sample identity		Other: WBC% Blasts	
	TEST(S)	REQUESTED	
	SEE PAGE 3 FOR SPEC	CIMEN AND TEST DETAILS	
Cytogenetic Chromosome and Microarray Analysis		Medulloblastoma Methylation Array (Microarray SNP)	
☐ Oncology Chromosome Analysis		Fresh tumor preferred, FFPE optional	
☐ Constitutional (blood) Chromosome Analysis		☐ Medulloblastoma Subgrouping & CNV Analysis**	
□ Oncology Microarray		☐ Medulloblastoma Subgrouping ONLY	
[Additional 3 mL blood or bone marrow (NaHep) if ordered without chromosomes] — % Tumor:		☐ Medulloblastoma CNV Analysis ONLY**	
		Molecular Genetic Analysis (RNA assays)	
FISH		Samples must be received within 24 hours of collection.	
(Additional FISH probes available. See page 3 for details.)		☐ BCR/ABL- QUANTITATIVE (p210)	
☐ t(9;22) [BCR/ABL1]	☐ 11q23 [KMT2A]	☐ BCR/ABL- QUANTITATIVE (p190)	
☐ X/Y [Opposite sex BMT]		☐ BCR/ABL - RT-PCR (QUALITATIVE)	
Other (please call lab)		□ PML/RARα - RT-PCR	
Hematologic FISH Panels		Molecular Genetic Analysis (DNA assays)	
(All probes available individually. Please see page 3 for panel descriptions)		Samples must be received within 48 hours of collection.	
☐ ALL Hyperdiploid	☐ Fanconi anemia	□ <i>JAK2</i> QUANTITATIVE (V617F)	
☐ ALL Risk Stratification	☐ Multiple myeloma	□ PTEN sequencing	
☐ Ph-like ALL	□MDS	☐ Bone marrow engraftment (BME) by STR (Same sex donor & recipient)	
□ AML	□ MPD	☐ Pre-transplant host sample	
□ APL	□SDS	☐ Post transplant sample	
☐ Burkitt Lymphoma	☐ Large cell NHL	☐ Donor sample	
□ CLL	☐ Small cell NHL	☐ WBC sub-populations engraftment study*	
☐ Double Hit Lymphoma	☐ Combined NHL		
☐ Eosinophilia	☐ T-Cell Lymphoma/Leukemia	☐ STR (same sex)	
		□ X/Y FISH (opposite sex)	
Non-Hematologic FISH Froch tumor or 2 FERE slides (m.	ust include 1 marked H & E slide with FFPE)	☐ Cell Separation (for non-engraftment testing)* *You MUST call the GENETICS LAB at 513-636-4474 to schedule this test	
,	ust include i marked in & E slide with FFFE)	prior to sample submission.	
□ BRAF (7q34) FISH □ Epondymoma FISH Panel			
☐ Ependymoma FISH Panel		Non-Hematologic Genetic Analysis	
☐ High-Grade Glioma FISH Panel		☐ MAP2K1 full gene sequence analysis (Langerhans cell histocystosis, colon, lung,	
☐ Low-Grade Glioma FISH Panel ☐ Lung Cancer FISH Panel		melanoma) — % Tumor:	
☐ Medulloblastoma FISH Panel			
☐ Melanocytic Tumor FISH Panel			
- molariocytic runnor Horred ICI			



ADDITIONAL INFORMATION

SPECIMEN REQUIREMENTS

Cytogenetic Analysis (Chromosome, FISH, and Microarray analysis):

3 mL blood or bone marrow (NaHep)

3 mL blood or bone marrow (EDTA)

Oncology microarray

Chromosome analysis

Cell culture only

FISH probes and FISH panels

Chromosome analysis

Cell culture

Cell Culture

FISH probes and FISH panels

saline or sterile transport media)

Fresh Tumor or Lymph Nodes (1cm³ in sterile

Molecular Genetic Analysis (RNA Assays): 5-10 mL blood or 3-5 mL bone marrow (EDTA) — Samples must be received within 24 hours of collection.

BCR/ABL — Quantitative (p210), BCR/ABL — Quantitative (p190), BCR/ABL — Qualitative, PML/RARa — Quantitative

Molecular Genetics Analysis (DNA Assays): 3 mL bone marrow or blood (EDTA) — Samples must be received within 48 hours of collection.

JAK2 Quantitative (V617F), PTEN Seq, Bone marrow engraftment by STR, WBC sorted sub-populations engraftment study (by STR or FISH)

Non-Hematologic Genetic Analysis:

MAP2K1 full gene sequencing:

3 mL blood or bone marrow (EDTA), 1 cm3 fresh tumor or 10 formalin fixed paraffin embedded (FFPE) tissue scrolls. Please send additional scrolls (if possible) for extremely small tissue samples.

FISH (Fluorescence In Situ Hybridization)

NOTE: All FISH probes are available for individual testing

Hematologic FISH Panels — 3 mL blood or bone marrow (NaHep)

- · ALL Hyperdiploid: trisomy 4, 10, 17
- ALL Risk Stratification: 4, 10, 17, t(1;19), t(12;21), t(9;22), KMT2A
- Ph-like ALL: CRLF2, ABL2, PDGFRB, CSF1R, JAK2, ABL1, EPOR
- AML: t(6;9), t(8;21), NUP98, KMT2A, inv(16)
- APL: t(15;17), RARa
- Burkitt Lymphoma: t(8;14), MYC
- CLL: 13q14.3, 13q34, 12 centromere, ATM, TP53, t(11;14)
- Double Hit Lymphoma: BCL6, MYC, t(8;14), t(14;18)
- Eosinophilia: 4q12, PDGFRB, FGFR1, CBFB
- Fanconi Anemia: 1q25, 3q27, mono 7 / del(7q)
- Multiple Myeloma (CD138+): 1p32.3/1q21, t(4;14), t(11;14), monosomy 13/del 13q, t(14;16), t(14;20), TP53
- MDS: mono 5/del 5g, mono 7/del 7g, tri 8, TP53, del (20g)
- MPD: 4q12, PDGFRB, FGFR1, BCR/ABL1

- SDS: mono 7/del 7q, tri 8, del (20q)
- Large cell NHL: t(11;14), t(14;18), TP53, BCL6, ALK
- Small B-cell NHL: t(11;14), t(14;18), 18q21 (MALT1), CLL Panel
- · Combined NHL: (large and small cell panels)
- T-Cell Lymphoma: TRA/TRD, TRB; TRG, BCR/ABL1, KMT2A

Non-Hematologic FISH Panels — 4-8 FFPE slides cut to 4 micron thickness and 1 marked H & E slide^{†*} — Fresh Tumor (1cm³)

- Ependymoma: ABL2, CDKN2A, C11orf95, RELA
- High-Grade Glioma: PDGFRA, CDKN2A, NTRK2, MYCN
- Low-Grade Glioma: TP73/ABL2, FGFR1, MYB, BRAF, MYBL1
- Lung Cancer: ALK, ROS1, MET, RET
- Medulloblastoma: MYB, LIS1/RARa, MYC, MYCN
- Melanocytic Tumor: RREB1, MYC, CDKN2A, CCND1
- Pilocytic Astrocytoma: BRAF, CDKN2A*

[†]For each probe ordered, send 2 unstained slides with one section cut to 4 micron thickness and mounted on a charged slide. Blocks are also accepted for processing.

*Pilocytic Astrocytoma FISH Panel only needs 2-4 FFPE slides and 1 marked H&E slide

Methylation Array Specimen Options:

- 1. Fresh Tumor Tissue (Preferred Specimen Type): Send 10–25 mg (1cm³) of STERILE tumor tissue in STERILE saline or transport medium (RPMI)
 - $a.\ Unacceptable\ Fresh\ Tumor\ Conditions:\ Specimen\ placed\ in\ formal in\ or\ non-sterile\ container.$
 - $b. \ Store \ at \ room \ temperature \ (if \ storing \ overnight, \ please \ \textbf{REFRIGERATE}). \ Use \ overnight \ shipping \ (protect \ from \ temperature \ extremes, \ no \ ice)$
- 2. Formalin Fixed Paraffin Embedded Tissue (FFPE) (Optional)**: A representative FFPE block or 10 unstained FFPE slides and 4 scrolls (2 eppendorf tubes with 2 scrolls each) with a tumor surface area of up to 250mm².
 - a. If a pathology evaluation has already been performed on the sample, send a copy of the pathology report and include any additional IHC or molecular testing that might have been performed.
- 3. DNA (Optional):** If DNA sample is available, please send 1ug DNA (max volume 90uL). DNA must have been extracted in a CLIA certified laboratory.

**ONLY MYC-N (2p24.3) amplification, GLI2 (2q14.2) amplification, Monosomy 6, MYC (8q24.21) amplification, 10q loss, Monosomy 11, 17p loss, 17q gain and isochromosome 17q will be reported for CNV Analysis performed on Formalin Fixed Paraffin Embedded (FFPE) tissue or DNA that was originally extracted from a FFPE sample.



ADDITIONAL INFORMATION, CONTINUED

For Chromosome Breakage Study for Fanconi Anemia - Please see Fanconi Anemia requisition (www.cincinnatichildrens.org/cytogenetics or call 513-636-4474)

SHIPPING INFORMATION

Local courier is available; please call 513-636-4474 for information.

Shipping:

For samples that arrive **Monday–Saturday:**Cincinnati Children's
Cytogenetic and Molecular Laboratories
3333 Burnet Ave.
TCHRF 1042
DOCK 5
Cincinnati, OH 45229-3039

BILLING INFORMATION

* PLEASE NOTE:

- We will not bill Medicaid, Medicaid HMO, or Medicare except for the following: CCHMC Patients, CCHMC Providers, or Designated Regional Counties.
- If you have questions, please call 1-866-450-4198 for complete details.

☐ Patient signed completed ABN

Medical Necessity Regulations: At the government's request, the Molecular Genetics Laboratories would like to remind all physicians that when ordering tests that will be paid under federal health care programs, including Medicare and Medicaid programs, that these programs will pay only for those tests the relevant program deems to be (1) included as covered services, (2) reasonable, (3) medically necessary for the treatment and diagnosis of the patient, and (4) not for screening purposes.